Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. Its pipeline includes four clinical-stage candidates: tovecimib (CTX-009), a DLL4/VEGF-A bispecific antibody in Phase 2/3 for biliary tract cancer; CTX-471, a CD137 agonistic antibody; CTX-8371, a PD-1/PD-L1 bispecific antibody in Phase 1; and CTX-10726, a PD-1/VEGF-A bispecific antibody in Phase 1 dose escalation. The company targets angiogenesis, immune activation, and tumor immunosuppression pathways.
expected 2026-12-22
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001171843-26-001337 | EDGAR | 81K words |
| 2025-02-27 | 2024-12-31 | 0001171843-25-001106 | EDGAR | 82K words |
| 2024-03-21 | 2023-12-31 | 0001171843-24-001516 | EDGAR | 84K words |
| 2023-03-15 | 2022-12-31 | 0001171843-23-001691 | EDGAR | — |
| 2022-03-18 | 2021-12-31 | 0000950170-22-004156 | EDGAR | — |
| 2021-03-05 | 2020-12-31 | 0001564590-21-011110 | EDGAR | — |
| 2020-06-08 | 2020-03-31 | 0001213900-20-014390 | EDGAR | — |
| 2019-07-01 | 2019-03-31 | 0001213900-19-011850 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001171843-26-005295 | EDGAR | 16K words |
| 2025-11-05 | 2025-09-30 | 0001171843-25-007005 | EDGAR | 14K words |
| 2025-08-11 | 2025-06-30 | 0001171843-25-005261 | EDGAR | 14K words |
| 2025-05-08 | 2025-03-31 | 0001171843-25-002953 | EDGAR | 12K words |
| 2024-11-12 | 2024-09-30 | 0001171843-24-006248 | EDGAR | 15K words |
| 2024-08-12 | 2024-06-30 | 0001171843-24-004670 | EDGAR | 14K words |
| 2024-05-13 | 2024-03-31 | 0001171843-24-002785 | EDGAR | 13K words |
| 2023-11-09 | 2023-09-30 | 0001171843-23-006912 | EDGAR | 18K words |
| 2023-08-03 | 2023-06-30 | 0001171843-23-004947 | EDGAR | 17K words |
| 2023-05-04 | 2023-03-31 | 0001171843-23-002868 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001171843-22-007269 | EDGAR | — |
| 2022-08-01 | 2022-06-30 | 0001171843-22-005187 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-22 | 0001171843-26-006162 | EDGAR | 1K words |
| 2026-08-06 | 0001171843-26-005292 | EDGAR | 2K words |
| 2026-03-05 | 0001171843-26-001336 | EDGAR | 2K words |
| 2026-01-06 | 0001171843-26-000083 | EDGAR | 1K words |
| 2025-11-05 | 0001171843-25-007004 | EDGAR | 3K words |
| 2025-08-13 | 0001193125-25-179958 | EDGAR | 1K words |
| 2025-08-11 | 0001171843-25-005260 | EDGAR | 3K words |
| 2025-06-12 | 0001171843-25-003868 | EDGAR | 1K words |
| 2025-05-08 | 0001171843-25-002952 | EDGAR | 2K words |
| 2025-04-01 | 0001171843-25-001900 | EDGAR | 1K words |
105 total filings indexed. 75 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001738021 |
| Ticker | CMPX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.compasstherapeutics.com |
| Listed | 2020-11-13 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CMPX (~200 tokens, structured JSON with cryptographic provenance)